ARWR

Arrowhead Pharmaceuticals, Inc.

Next est. report 2026-11-24 · AMC

Biotech '24: Pharma/TherapeuticsBiotech '25: RNA-Based/Genetic MedicineGLP-1 Long '26: RNA Fat Redistribution

Loading…

Loading chart…

Overview

Arrowhead Pharmaceuticals develops RNAi-based medicines for complex diseases, with a focus on cardiometabolic and CNS disorders. Its lead product, REDEMPLO, is

Arrowhead Pharmaceuticals develops RNAi-based medicines for complex diseases, with a focus on cardiometabolic and CNS disorders. Its lead product, REDEMPLO, is approved for Familial Chylomicronemia Syndrome and recently showed positive Phase III results for severe hypertriglyceridemia, a larger market opportunity. Revenue is generated from product sales and strategic collaborations with pharmaceutical partners.

Search Keywords Brand Product

REDEMPLO
plozasiran
zodasiran
ARO-DIMER-PA
ARO-INHBE
ARO-MAPT
Tryngolza
RNA interference therapeutics
gene silencing drugs
severe hypertriglyceridemia treatment
familial chylomicronemia syndrome
obesity drugs
NASH treatment
Alzheimer's disease therapy
cardiometabolic franchise
APOC3 inhibitor
PCSK9 inhibitor
tauopathies

Search Keywords Event Phrases

SHASTA-3 results
SHASTA-4 results
ESC Congress 2026
ARO-DIMER-PA data readout
ARO-MAPT data readout

Search Keywords Policy Regulatory

FDA Priority Review Voucher
sNDA submission
Breakthrough Therapy Designation
Orphan Drug Designation
marketing authorization

What They Do (Plain English & Analogies): Arrowhead Pharmaceuticals is a biopharmaceutical company that develops medicines to treat serious diseases by 'silencing' the genes that cause them. Imagine a disease is like a faulty instruction manual in your body's cells, telling them to make too much of a harmful protein. Arrowhead's drugs, using a technology called RNA interference (RNAi), act like a censor that intercepts and destroys these faulty instructions before the harmful protein can even be made. This stops the disease at its source. Their lead product, REDEMPLO, helps people with very high levels of fats (triglycerides) in their blood, which can lead to serious problems like pancreatitis. They are also working on treatments for obesity, liver diseases, and brain disorders like Alzheimer's.
Very Brief History: Founded in 1989 and based in Pasadena, California, Arrowhead Pharmaceuticals has evolved into a prominent RNAi-focused biotech. The company's strategic identity is anchored by its APOC3-targeting franchise. A significant milestone was the FDA approval of REDEMPLO (plozasiran) in November 2025 for familial chylomicronemia syndrome (FCS). More recently, in July 2026, they reported positive top-line Phase III results for plozasiran in severe hypertriglyceridemia (sHTG), marking a major clinical achievement and setting the stage for a broader market opportunity.
"Street Stereotype": Arrowhead Pharmaceuticals is generally perceived as a promising, high-growth biotechnology company with a validated RNAi platform and a significant commercial opportunity. Investors and analysts are particularly focused on the potential label expansion of REDEMPLO into the much larger severe hypertriglyceridemia (sHTG) market, which is seen as a major value driver. The company is also recognized for its robust pipeline and strategic partnerships, positioning it as an innovator in gene-silencing therapeutics.
Subsidiaries On Linked In*: Arrowhead Madison Inc.
Arrowhead Australia Pty Ltd.
Arrowhead Pharmaceuticals NZ Ltd.
Arrowhead Pharmaceuticals Ireland Ltd.
Visirna Therapeutics Inc.
Customer Sectors & Example Clients: Arrowhead's direct customers are healthcare providers (physicians, specialists like cardiologists and endocrinologists) who prescribe their medicines to patients. Their indirect customers are patients suffering from diseases like familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG). The company also engages in strategic collaborations and licensing agreements with other pharmaceutical companies, which act as partners or clients for specific programs or geographies. Example clients/partners include Sarepta, Madrigal, Novartis, Sanofi (for Greater China), Janssen Pharmaceuticals, and Takeda Pharmaceuticals.
New Customers / Segments They'Re Targeting: Arrowhead is actively targeting a substantially larger patient population with severe hypertriglyceridemia (sHTG) for its drug REDEMPLO, beyond its initial approval for the rare familial chylomicronemia syndrome (FCS). This expansion aims to reach patients with triglycerides above 500 mg/dL, including those at high risk of acute pancreatitis. Additionally, the company is developing new candidates like ARO-INHBE and ARO-ALK7 to target obesity and NASH, and ARO-MAPT for tauopathies, including Alzheimer's disease, representing a new segment in central nervous system (CNS) disorders.
Sales Geographies And Expansion Plans: REDEMPLO is currently approved for FCS in the United States, Canada, China, Australia, and the European Union. Sanofi leads commercialization in Greater China. Arrowhead is working through country-specific reimbursement and launch processes in the EU, starting with Germany in the coming weeks. The company intends to submit a supplemental New Drug Application (sNDA) to the FDA for sHTG before the end of 2026, followed by additional global filings, reflecting a strategy to expand marketing authorization across multiple geographies simultaneously for this broader indication.
How Key Themes May Help/Hurt: The 'GLP-1 Long '26: RNA Fat Redistribution' theme is highly beneficial for Arrowhead. The theme emphasizes a shift in obesity treatment towards improved body composition and the potential of RNA therapeutics for superior efficacy and durability. Arrowhead's pipeline includes ARO-INHBE and ARO-ALK7, which are obesity and NASH candidates utilizing RNAi technology, directly aligning with this theme's focus on novel mechanisms for cardiometabolic diseases. Positive developments in this theme, such as increasing demand for advanced obesity treatments and validation of RNA therapeutics, could accelerate the development and commercial success of Arrowhead's related programs. The 'Biotech '24: Pharma/Therapeutics' theme also helps by highlighting a favorable regulatory environment and the value of strategic partnerships, both of which are central to Arrowhead's business model and pipeline advancement.

3 Main Long-Term Bull Details

Broad Commercial Opportunity: The positive Phase III data for REDEMPLO in severe hypertriglyceridemia (sHTG) positions the drug for a substantially larger market opportunity than its current familial chylomicronemia syndrome (FCS) indication, with potential peak sales estimated in the $3 billion to $4 billion range annually.
Robust and Scalable Pipeline & Platform: Arrowhead possesses a diverse pipeline of 23 drug candidates (11 wholly owned, 12 partnered) leveraging its proprietary Targeted RNAi Molecule (TRiM™) platform, which has demonstrated successful translation from animal models to humans across various targets including liver, adipose, muscle, lung, and CNS. This provides substantial future growth potential beyond REDEMPLO.
Strong Financial Position and Strategic Partnerships: The company has a strong balance sheet with approximately $1.6 billion in cash and investments as of June 30, 2026, providing significant financial flexibility. Its strategy includes valuable licensing and collaboration agreements (e.g., with Sarepta, Madrigal, Novartis, Sanofi, Janssen, Takeda) that provide upfront payments, milestones, and royalties, de-risking development and expanding global reach.

3 Main Long-Term Bear Details

Intense Market Competition: The obesity and cardiometabolic treatment markets are becoming increasingly competitive, with established players and new entrants (e.g., Ionis Pharmaceuticals with Tryngolza in sHTG) creating pricing pressure and potential market share erosion.
Regulatory and Payer Scrutiny: Novel therapies, especially those with premium pricing, face significant scrutiny from regulators and payers to demonstrate superior clinical differentiation and cost-effectiveness for favorable reimbursement and broad market access. Delays or unfavorable coverage decisions could impact revenue potential.
Clinical Development Risks: Despite a strong track record, inherent clinical development risks persist for novel RNA therapies. Pipeline assets, including those in earlier stages, face the potential for trial failures, unexpected safety signals, or delays in regulatory approvals, which could significantly impact their market entry and commercial viability.

Competitors And Differentiation: In the severe hypertriglyceridemia (sHTG) market, Arrowhead's primary competitor is Ionis Pharmaceuticals with its drug Tryngolza (olezarsen). Arrowhead differentiates REDEMPLO (plozasiran) through its impressive efficacy, demonstrating deep and durable triglyceride reductions (79-81% median reduction) and a statistically significant reduction in acute pancreatitis events (78% overall, 100% in highest-risk patients). Key differentiators also include a favorable safety and tolerability profile with no new safety signals, no clinically meaningful liver enzyme issues, and no increase in liver fat. Furthermore, REDEMPLO offers simpler quarterly dosing and a consistent 25mg dose for all patients, compared to competitors that may require more frequent dosing or liver enzyme monitoring.
Recent Performance & What The Market'S Focused On: Arrowhead recently reported a net loss of $194.3 million for its fiscal 2026 third quarter, with revenue totaling approximately $75 million, more than doubling the prior year's quarter. The company has seen greater than a doubling of REDEMPLO prescriptions quarter-on-quarter for FCS. The market is primarily focused on the positive top-line Phase III results for plozasiran in sHTG (SHASTA-3 and SHASTA-4), which demonstrated deep triglyceride reductions and a significant reduction in acute pancreatitis events. Key upcoming events include the detailed presentation of SHASTA data at the European Society of Cardiology Congress (August 30, 2026), the planned sNDA submission for plozasiran in sHTG before the end of 2026 (accelerated by a priority review voucher), and upcoming data readouts for ARO-DIMER-PA, ARO-MAPT (in September), ARO-INHBE, and ARO-ALK7 (in Q4 2026).

Revenue Segments And Estimated Mix: Sarepta collaboration — Mix: ~34.7%; Source: Q3 2026 transcript
Novartis collaboration — Mix: ~26.7%; Source: Q3 2026 transcript
Madrigal upfront payment — Mix: ~33.3%; Source: Q3 2026 transcript; Trend: Full $25M recognized
Sanofi (transitional services & FCS supply) — Mix: ~1.6%; Source: Q3 2026 transcript
Commercial REDEMPLO sales — Mix: ~3.2%; Source: Q3 2026 transcript; Trend: More than doubled from Q2
Product Brands: REDEMPLO
plozasiran
zodasiran
ARO-DIMER-PA
ARO-INHBE
ARO-ALK7
ARO-MAPT
ARO-PNPLA3
ARO-AAT
ARO-APOC3
ARO-ANG3
ARO-HIF2
ARO-HSD
ARO-ENaC
ARO-C3
ARO-Lung2
ARO-DUX4
ARO-XDH
ARO-COV
JNJ-3989
Olpasiran
ARO-AMG1
ARO-JNJ1
ARO-JNJ2
ARO-JNJ3

Bull / Bear Details

Arrowhead Pharmaceuticals maintains a bullish outlook as of 2026-08-31, driven by positive Phase III SHASTA data for REDEMPLO in severe hypertriglyceridemia, si

Thesis

Arrowhead Pharmaceuticals maintains a bullish outlook as of 2026-08-31, driven by positive Phase III SHASTA data for REDEMPLO in severe hypertriglyceridemia, significantly expanding its market opportunity with accelerated regulatory review. The company's robust RNAi pipeline, including promising cardiometabolic and CNS programs, coupled with a scalable commercial infrastructure, positions it for substantial long-term growth. Challenges include intense market competition and ongoing regulatory hurdles.

Bull case

REDEMPLO's positive Phase III SHASTA data for severe hypertriglyceridemia (sHTG) demonstrated deep and durable triglyceride reductions (79-81%) and a 78% reduction in acute pancreatitis events, with a clean safety profile. The acquisition of a priority review voucher aims to accelerate sNDA submission by year-end 2026 and potential approval, targeting a $3B-$4B peak sales opportunity.
Arrowhead boasts a diverse and advancing RNAi pipeline beyond REDEMPLO, with key upcoming data readouts. This includes ARO-DIMER-PA (dual PCSK9/APOC3) and ARO-MAPT (subcutaneous CNS delivery) in September, and ARO-INHBE/ARO-ALK7 for obesity/NASH in Q4, validating the platform's broad applicability and potential for multiple future products.
The successful U.S. launch of REDEMPLO for FCS, with prescriptions more than doubling quarter-on-quarter, provides a valuable and scalable commercial foundation. This infrastructure is being expanded to address the much larger sHTG market (targeting over 20,000 HCPs), enabling cost-effective growth for its cardiometabolic franchise.

Bear case

The cardiometabolic and obesity treatment markets are becoming increasingly competitive, with established players and new entrants, including GLP-1s and other RNAi therapies. This intense competition could lead to significant pricing pressure and erode market share for REDEMPLO and future pipeline assets, impacting profitability.
Despite strong clinical data, regulatory and payer scrutiny remains a significant challenge for novel therapies like plozasiran in sHTG. Securing favorable reimbursement and broad market access will require clear clinical differentiation and demonstrated cost-effectiveness, especially as the market requires extensive physician and patient education.
The inherent clinical development risks associated with a broad RNAi pipeline persist. While Arrowhead has a strong track record, potential trial failures, unexpected safety signals, or delays in regulatory approvals for its numerous candidates could significantly impact market entry, commercial viability, and investor confidence.

Bull / Bear Case

Bear Case: The bear case for Arrowhead Pharmaceuticals is primarily centered on intense market competition within the cardiometabolic and obesity treatment sectors. The entry of established players and new RNAi therapies, alongside the rapid expansion of GLP-1s, could lead to significant pricing pressure and erode market share for REDEMPLO and future pipeline assets. Despite strong clinical data, regulatory and payer scrutiny remains a substantial challenge for novel therapies with premium pricing, necessitating clear clinical differentiation and demonstrated cost-effectiveness for broad market access. The sHTG market is new and will require extensive physician and patient education, potentially leading to a slower-than-anticipated commercial ramp. Additionally, inherent clinical development risks persist across Arrowhead's broad RNAi pipeline, with potential for trial failures, unexpected safety signals, or delays in regulatory approvals impacting market entry and commercial viability. Uncertainty around Most-Favored-Nations (MFN) policies also complicates revenue projections from ex-U.S. markets.
Bull Case: Arrowhead Pharmaceuticals presents a compelling bull case driven by the positive Phase III SHASTA data for REDEMPLO in severe hypertriglyceridemia (sHTG), demonstrating deep (79-81% median) triglyceride reductions and a significant 78% decrease in acute pancreatitis events with a clean safety profile. This expands REDEMPLO's market opportunity to a potential $3 billion to $4 billion in peak sales. The acquisition of a priority review voucher aims to accelerate sNDA submission by year-end 2026 and potential approval. The successful U.S. launch of REDEMPLO for FCS provides a scalable commercial foundation, expanding to target over 20,000 HCPs for sHTG. Furthermore, a diverse RNAi pipeline, including ARO-DIMER-PA, ARO-MAPT (CNS delivery), ARO-INHBE, and ARO-ALK7, with numerous upcoming data readouts, validates the platform's broad applicability and potential for multiple future products. The company maintains a strong balance sheet with $1.6 billion in cash and investments, supporting ongoing development and commercialization.
More Compelling & Why: Bear. Despite strong clinical data for REDEMPLO in sHTG, the stock's underperformance relative to the SPY since the earnings call suggests that the current valuation, likely reflected in a high Price/Sales ratio given limited current revenue, already prices in much of the future potential. The market appears to be discounting the significant execution risks in a highly competitive cardiometabolic and obesity market, coupled with the need for extensive market education and potential payer scrutiny. My view would flip if ARWR demonstrated faster-than-expected commercial traction for REDEMPLO in sHTG, leading to a significant upward revision in near-term revenue forecasts and a more reasonable forward P/S multiple.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Plozasiran sNDA Submission for sHTG	This submission, accelerated by a priority review voucher, is a critical step towards expanding REDEMPLO into the much larger severe hypertriglyceridemia (sHTG) market, which management believes could drive peak sales of $3 billion to $4 billion annually.	Confirmation of the sNDA submission to the FDA for plozasiran in sHTG, specifically before the end of 2026.	Submission of the sNDA by year-end 2026 = bullish signal, indicating progress towards market expansion and leveraging the priority review voucher. Delay beyond year-end 2026 = bearish signal.	Company press releases, SEC filings (e.g., Form 8-K), FDA website. Expected before end of 2026.	FDA website (drug approvals, submissions), industry news outlets (Fierce Biotech, Endpoints News).	EvaluatePharma: Market forecasts for plozasiran in sHTG.
ARO-MAPT Phase I Data Readout (Healthy Volunteers)	This readout represents the first clinical proof-of-concept for Arrowhead's subcutaneously administered CNS delivery platform, opening up a vast new therapeutic area (tauopathies, Alzheimer's) for their RNAi technology.	Top-line data release from the Phase I study of ARO-MAPT in healthy volunteers in September 2026. Specifically, look for safety data and total tau knockdown levels.	Achievement of 50% to 60% total tau knockdown with a favorable safety profile = bullish signal, validating the CNS delivery platform. Lower knockdown or significant safety concerns = bearish signal.	Company press releases, investor presentations, scientific conferences. Expected in September 2026.	ClinicalTrials.gov (updates on study status), Alzheimer's Association news.	Citeline (formerly Informa Pharma Intelligence): Pipeline intelligence and competitive analysis for CNS RNAi therapies.
Detailed SHASTA-3 and SHASTA-4 Data Presentation at ESC	The detailed presentation of positive Phase III data for plozasiran in sHTG at a major cardiology conference will provide further validation of its efficacy and safety, influencing physician adoption and market perception.	Full data presentation at the European Society of Cardiology Congress on August 30, 2026, and the Arrowhead webcast on August 31, 2026. Specifically, look for detailed triglyceride reduction (median vs. mean), responder analyses (below 500 mg/dL, below 150 mg/dL), and comprehensive safety data (liver fat, ALT elevations, glycemic parameters).	Confirmation of deep, durable, and consistent triglyceride reductions (e.g., median 79-81%) and significant acute pancreatitis event reduction (e.g., 78% overall, 100% in high-risk) with a clean safety profile = bullish signal. Any unexpected safety signals, less favorable responder analysis, or significant imbalances in liver fat/ALT elevations = bearish signal.	European Society of Cardiology Congress website (abstracts, presentations), Arrowhead Pharmaceuticals investor relations website (webcast replay, press release). August 30-31, 2026.	Social media (Twitter/X, Reddit: r/medicine, r/cardiology) for real-time reactions and expert commentary. Industry news coverage.	KOL surveys (e.g., Spherix Global Insights): Physician sentiment and prescribing intent post-data release.
ARO-DIMER-PA Phase I Data Readout	This is the first clinical data for a novel dual-functional siRNA targeting both APOC3 and PCSK9, potentially offering a uniquely powerful therapy for mixed hyperlipidemia and expanding Arrowhead's cardiometabolic pipeline.	Top-line data release from the Phase I study of ARO-DIMER-PA in September 2026. Look for dose-dependent reductions in both LDL cholesterol and triglycerides.	Significant, dose-dependent reductions in both LDL-C and triglycerides, with a favorable safety profile = bullish signal, validating the dual-targeting approach. Lack of significant reductions or unexpected safety issues = bearish signal.	Company press releases, investor presentations, scientific conferences. Expected in September 2026.	ClinicalTrials.gov (updates on study status), industry news.	BioCentury: Analyst reports and competitive landscape analysis for mixed hyperlipidemia therapies.
ARO-INHBE and ARO-ALK7 Data Releases	These updates provide further insights into Arrowhead's novel non-incretin obesity strategy, aligning with the broader theme of 'RNA Fat Redistribution' and diversifying their approach to a major metabolic disease.	Additional data releases for ARO-INHBE and ARO-ALK7 in the fourth quarter of 2026. For ARO-INHBE, look for further details on liver fat reduction, body weight, and body composition. For ARO-ALK7, look for the specific obesity data update.	Continued demonstration of significant liver fat reduction (e.g., >30-44% placebo-adjusted), positive effects on body weight/composition, and favorable safety for ARO-INHBE and ARO-ALK7 = bullish signal. Lack of further improvement or new safety signals = bearish signal.	Company press releases, investor presentations, scientific conferences. Expected in Q4 2026.	ClinicalTrials.gov (updates on study status), obesity research forums.	Spherix Global Insights: Physician surveys on novel obesity treatments and their perceived differentiation.

Key Reported Metrics, Reratings Triggers & Results3 rows

SG&A expense reflects Arrowhead's investment in commercialization efforts for REDEMPLO and building infrastructure for the potential sHTG launch. Growth indicat

Upcoming print · 2026-11-24

Key reported metrics
Metric	Last period	Why it matters
SG&A Expense	51.61%	SG&A expense reflects Arrowhead's investment in commercialization efforts for REDEMPLO and building infrastructure for the potential sHTG launch. Growth indicates scaling for market expansion, but also impacts profitability.
R&D Expense	22.22%	R&D expense is crucial for a biotechnology company, indicating investment in pipeline development. High R&D signals commitment to future growth and advancing drug candidates, but also impacts the company's burn rate.
Total Revenue	167.86%	Total Revenue is a key indicator of Arrowhead's overall financial health and growth. For a biotech, it reflects success in collaboration agreements and early product commercialization, signaling market acceptance and pipeline value.

Key Questions

Will Arrowhead Pharmaceuticals successfully submit the sNDA for plozasiran in sHTG by year-end 2026 and effectively execute its commercial build-out for an acce

Will Arrowhead Pharmaceuticals successfully submit the sNDA for plozasiran in sHTG by year-end 2026 and effectively execute its commercial build-out for an accelerated Q2 2027 launch, following the positive ESC data presentation?

Question 2: Will the September clinical readouts for ARO-DIMER-PA and ARO-MAPT validate Arrowhead's dual-targeting approach for cardiometabolic diseases and its novel subcutaneous CNS delivery platform, respectively?
Question 3: How effectively can Arrowhead Pharmaceuticals secure broad payer coverage and differentiate REDEMPLO's premium pricing in the sHTG market, given the competitive landscape and the need for extensive market education?

Earnings Transcript SummaryTable

2026-08-04 · 2026Q3 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Accelerating REDEMPLO's sHTG Approval and Launch: Management is highly focused on rapidly bringing plozasiran to patients with severe hypertriglyceridemia (sHTG), having acquired a priority review voucher to potentially accelerate the U.S. regulatory review process from 10 months to 6 months. They intend to submit a supplemental New Drug Application (sNDA) to the FDA before the end of 2026, leveraging strong Phase III SHASTA data. 2. Expanding the Cardiometabolic Franchise: Beyond plozasiran, management aims to build a broader cardiometabolic franchise, including zodasiran, ARO-DIMER-PA, and new obesity treatments (ARO-INHBE, ARO-ALK7). This strategy is designed to utilize existing commercial channels for scalability and cost-effective growth. 3. Advancing a Diverse Pipeline with Key Data Readouts: The company is committed to progressing its extensive pipeline, with significant upcoming data readouts. These include the first clinical readouts for ARO-DIMER-PA and ARO-MAPT (a subcutaneously administered CNS delivery platform for tauopathies) in September, and additional data for ARO-INHBE and ARO-ALK7 in the fourth quarter. They anticipate having 23 drug candidates in clinical trials by year-end.	Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Management conveyed strong optimism regarding the positive Phase III SHASTA data for plozasiran in severe hypertriglyceridemia (sHTG) and its potential to significantly expand the commercial opportunity for REDEMPLO. The tone was upbeat, emphasizing the company's robust financial position, the successful momentum of the REDEMPLO FCS launch, and the scalability of their commercial infrastructure. Key themes included accelerating regulatory pathways, advancing a deep and diverse pipeline with numerous upcoming data readouts, and the long-term value creation potential from their RNAi platforms across multiple therapeutic areas.	Prior Quarter'S Y/Y Growth By SegmentFor the fiscal second quarter ended March 31, 2026, Arrowhead Pharmaceuticals reported total revenue of $74 million. This compares to $542.71 million in the prior year quarter (Q2 2025), representing an -86.36% year-over-year decline. The significant year-over-year decrease in Q2 2026 was primarily driven by lower Sarepta collaboration revenue compared to the prior year quarter, which included over $540 million related to the Sarepta transaction. Commercial REDEMPLO product sales in fiscal Q2 2026 were approximately $1 million.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. sNDA Submission Timeline and ESC Data Details: Analysts pressed on the specific timeline and gating factors for the sNDA submission for plozasiran in sHTG by year-end 2026, and sought more details on the European Society of Cardiology (ESC) late-breaker data, particularly regarding triglyceride reduction metrics and any safety imbalances. Management Response: James Hamilton stated they plan a pre-sNDA meeting with the FDA and are focused on generating necessary modules and reports for submission by year-end. He reiterated that they are under embargo for ESC data and cannot provide details until the conference. 2. ARO-MAPT Top-Line Data Expectations and Knockdown Targets: Analysts inquired about the specific top-line data expected for ARO-MAPT in September and the target level of tau knockdown, especially in the context of recent competitor data. Management Response: James Hamilton clarified that the September readout would be healthy volunteer data, focusing on safety and total tau knockdown. He maintained the target of 50% to 60% knockdown, noting it aligns with levels that showed clinical improvement in a previous study. 3. Commercial Strategy for sHTG (Sales Force, Segmentation, Pricing): Analysts questioned the planned size and sequencing of the sales force for the sHTG launch, whether the initial focus would be on the highest-risk patients or a broader population, and the pricing strategy for REDEMPLO compared to competitors. Management Response: Andy Davis indicated a scaling up of the field force to address over 20,000 HCP targets, with final onboarding before year-end for an anticipated accelerated Q2 2027 sHTG launch. He stated the initial focus would be on high-risk sHTG patients, but the data supports broader use. Chris Anzalone affirmed that the $45,000 per year price for REDEMPLO would not change, asserting that its differentiated efficacy, safety profile, and convenience (quarterly dosing, no liver enzyme monitoring, simple 25mg dose) justify a premium over competitors.	Revenue SegmentsTotal revenue for the quarter ended June 30, 2026, was approximately $75 million, compared to $28 million in the prior year quarter, representing a 167.86% year-over-year growth. Revenue was driven by collaboration agreements, with approximately $26 million from Sarepta, $20 million from Novartis, and the full $25 million upfront payment from Madrigal. Additionally, approximately $1.2 million was recognized for transitional services and commercial FCS supply to Sanofi. Commercial REDEMPLO product sales were approximately $2.4 million for the quarter, more than double the approximately $1 million recorded in fiscal quarter 2.

Transcript TidbitsTable

2026-08-04

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketArrowhead Pharmaceuticals expects sHTG to be a substantially larger commercial opportunity than FCS, allowing them to leverage existing infrastructure for a broader patient population. The company acquired a priority review voucher to accelerate the regulatory review process in the United States from 10 months to 6 months for REDEMPLO in sHTG. REDEMPLO's U.S. launch for FCS has seen prescription volume more than double quarter-on-quarter, with over 400 unique prescribers. The company has expanded REDEMPLO's reach internationally, with approvals in the United States, Canada, China, Australia, and the European Union for FCS. In Europe, REDEMPLO is the only therapy with clinical FCS on label, covering both genetically confirmed and clinically diagnosed patients, which is seen as a meaningful differentiator. For sHTG, the company plans to move from addressing over 5,000 HCP targets to over 20,000 HCP targets, including primary care physicians who act like specialists. They believe sHTG represents a very large market opportunity with many patients needing triglyceride control, though it will require significant education as it's a new market.	About CompetitionArrowhead believes REDEMPLO offers physicians and patients a best-in-class option, confident in its clinical data and commercial model for FCS and the potential sHTG launch. The company justifies a slight premium price for REDEMPLO over competitors due to its better safety profile, superior triglyceride reduction, simpler quarterly dosing, lack of anticipated need for liver enzyme monitoring, and a single 25-milligram dose for all patients. The acquisition of a priority review voucher is also intended to shorten competitors' first-mover advantage. The broader obesity treatment market is intensely competitive, with new entrants and existing players challenging current GLP-1 leaders, leading to pricing pressure and potential erosion of market share.	About The Broader IndustryThe overall regulatory environment is favorable, with an accelerated approval process for innovative treatments, particularly in oncology and rare diseases. Advancements in RNA therapeutics, including RNAi and RNA editing, are introducing novel mechanisms for obesity and cardiometabolic diseases. The GLP-1 market is rapidly expanding due to strong demand, increased patient access, and successful launches of oral formulations. Arrowhead noted that the uncertainty around Most-Favored-Nations (MFN) policies makes it difficult to project revenue from ex-U.S. markets. The company also highlighted that the sHTG market is new and will require significant education for both physicians and patients, as the world is not accustomed to closely monitoring triglycerides due to a historical lack of effective treatments.	Where Things Are HeadedArrowhead intends to submit a supplemental New Drug Application (sNDA) for plozasiran in sHTG to the FDA before the end of 2026, followed by additional global filings. They expect to file a Clinical Trial Application (CTA) for a new obesity candidate by the end of this year. Data from the Zodasiran YOSEMITE Phase III study in HoFH patients is anticipated in Q3 2027, with an NDA filing expected by the end of 2027. Early data from the Phase I study of ARO-DIMER-PA and ARO-MAPT are expected in September. By the end of 2026, Arrowhead anticipates having 23 individual drug candidates in clinical trials, with high confidence that most could be approved. The company expects costs associated with the SHASTA studies to moderate down starting in fiscal 2027, while continuing investments in regulatory activities, commercial supply readiness for sHTG, and pipeline advancement. They also anticipate an inflection point in REDEMPLO prescriptions and patient shipments as new field personnel are onboarded.	Updates On ThemeRNA	Broader Themes EmergingA significant shift in obesity treatment is occurring, moving beyond mere weight loss to focus on improved body composition, specifically targeting visceral fat reduction while preserving muscle mass. The GLP-1 market is experiencing rapid expansion, driven by strong demand, increased patient access, and the successful launch of oral formulations.	Bullish-Leaning Quotes (Short)Arrowhead is now on the strongest footing in its history. REDEMPLO is a needed therapy for sHTG patients. Both studies met their primary endpoint and every prespecified secondary endpoint, a clean sweep across 2 pivotal trials. Cumulative acute pancreatitis events were reduced by 78% versus placebo. In the highest risk subgroup... we saw a 100% reduction in events versus placebo. This is a clearly compelling value proposition for patients, health care providers and payers. Our U.S. REDEMPLO launch for FCS continued to build real momentum during the quarter. We believe REDEMPLO offers physicians and patients a best-in-class option. We believe these are best-in-class results. We believe that Arrowhead is something truly unique in biotech today. We have a high degree of confidence that the overwhelming majority of these could eventually be approved products.	Bearish-Leaning Quotes (Short)The obesity treatment market is becoming intensely competitive, with new entrants and existing players... challenging the dominance of current GLP-1 leaders. Regulatory and payer scrutiny remains a significant headwind. Inherent clinical development risks persist for novel RNA therapies. Given the uncertainty around MFN, it's very difficult for us to... know how these are going to be pursued in ex U.S. markets. This is going to be a relatively slow ramp because this is a brand-new market.	HiringArrowhead's field organization is scaling in a deliberate, sequenced way to address both the current FCS opportunity and the future sHTG opportunity. The company recently onboarded the next wave of field personnel, who will be in the field this month. They anticipate the final onboarding and optimization of their field force before the end of the year in preparation for a potential accelerated sHTG launch. Increased headcount to support manufacturing operations and a broader clinical pipeline contributed to higher salaries. The increase in SG&A expense was primarily driven by ongoing investments in REDEMPLO commercialization, including commercial headcount. They have expanded and continue to expand their commercial footprint and capabilities where appropriate, designing them to scale for future indications.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-08-04	Arrowhead Pharmaceuticals reported strong Q3 revenue and reiterated confidence in REDEMPLO's sHTG expansion and a robust pipeline with upcoming data. Despite bullish messaging and positive SHASTA data, ARWR stock underperformed SPY by over 2% (T+2 days). This market reaction suggests investors may have had higher expectations, or are weighing competitive pressures and regulatory hurdles against the positive outlook.	Earnings Transcript	Neutral		-2.17% (vs SPY: -2.42%)

Upcoming Events4 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
ARWR_f05e6e24	in September	2026-09-01	2026-09-30	Top-line data release from the Phase I/IIa study of ARO-DIMER-PA in patients with mixed hyperlipidemia.	ARO-DIMER-PA is designed to silence both APOC3 and PCSK9, potentially offering a uniquely powerful therapy for a large patient population with both elevated LDL cholesterol and triglycerides. Positive early data would de-risk this novel program.	Ticker	2026-08-04	earnings_transcript
ARWR_fd802403	this September	2026-09-01	2026-09-30	Top-line data release from the Phase I study of ARO-MAPT in healthy volunteers.	This could provide the first clinical proof of concept for Arrowhead's subcutaneously administered CNS delivery platform, validating its ability to address brain targets with RNAi and paving the way for future tauopathy clinical trials.	Ticker	2026-08-04	earnings_transcript
ARWR_0ccb6a5e	before the end of 2026	2026-10-01	2026-12-31	Submission of supplemental New Drug Application (sNDA) for plozasiran in severe hypertriglyceridemia (sHTG) to the FDA.	This is a critical regulatory step towards expanding the label for REDEMPLO, potentially opening up a substantially larger commercial opportunity with peak sales estimated at $3 billion to $4 billion per year.	Ticker	2026-08-04	earnings_transcript
ARWR_515ff5df	in the fourth quarter	2026-10-01	2026-12-31	Additional data releases from the ARO-INHBE and ARO-ALK7 programs.	These programs represent novel non-incretin strategies for obesity and NASH, and further positive data would build on encouraging early results, potentially de-risking these assets in high-demand markets.	Ticker	2026-08-04	earnings_transcript